N1 esophageal carcinoma: The importance of staging and downstaging  by Rice, Thomas W. et al.
454
of early-stage adenocarcinoma. Second, effective thera-
peutic alternatives were developed and include nonsur-
gical palliation and multimodality therapy. Third,
advances in clinical staging technology allowed deter-
mination of clinical (pretreatment) stage. Along with
these, the introduction of an accurate and practical stag-
ing system made it possible to use clinical stage for
prognosis and treatment modification.
Patients clinically staged with cancers metastatic to
regional lymph nodes (N1) have a poor prognosis if
treated with surgery alone. It is known that patients who
have no residual cancer after induction chemoradiation
therapy have an improved survival. However, no study
has clinically staged patients and quantified the benefit
of downstaging from N1 to N0, regardless of primary
tumor status. Therefore, the purpose of this study was to
evaluate clinical staging and downstaging by induction
chemoradiation therapy in patients with clinical N1
(cN1) esophageal carcinoma.
Fundamental changes in epidemiology, staging, andtherapy have transformed the treatment of eso-
phageal carcinoma.1,2 Previously, advanced-stage can-
cer and surgical therapy predominated. Now, multiple
therapeutic options are available for a heterogeneous
disease. These fundamental changes had several ori-
gins. First, a radical shift in the characteristics of the
disease resulted in the detection of increasing numbers
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Patients and methods
Patients. Between 1983 and 1999, 577 patients with
esophageal carcinoma underwent resection at The Cleveland
Clinic Foundation. From this database, 293 patients were
identified with known clinical (pre-induction therapy) and
pathologic N status (Table I). Of these, 69 had clinical N1
(cN1) disease and received preoperative induction therapy.
Thirty-seven were downstaged to pathologic N0 (cN1/pN0,
group 1) and 32 were not (cN1/pN1, group 2). To provide a
lower limit of comparative survival, we identified 75 patients
with both clinical and pathologic N1 who underwent surgery
without induction therapy (cN1/pN1, group 3). To provide an
upper limit of comparative survival, we identified 79 patients
with neither clinical nor pathologic N1 who underwent
surgery without induction therapy (cN0/pN0, group 4).
Of the 8 possible combinations of cN/pN and induction
therapy, 4 additional groups were identified: 23 patients
receiving induction therapy because of advanced clinical
depth of tumor invasion (cT), with neither clinical nor patho-
logic N1 (cN0/pN0, group 5); 8 patients receiving induction
therapy who were either understaged or had disease progres-
sion (cN0/pN1, group 6); 21 patients undergoing surgery
without induction therapy who were understaged (cN0/pN1,
group 7); and 18 patients undergoing surgery without induc-
tion therapy who were overstaged (cN1/pN0, group 8).
The addition of groups 5 through 8 was the strategy used to
quantify and adjust for clinical staging inaccuracies.
Of the 293 patients, 240 (82%) were men, 276 (94%) were
white, and age ranged from 26 to 84 years (mean ± SD, 62 ±
11). A total of 232 (79%) patients had adenocarcinoma, 57
(19%) patients had squamous cell carcinoma, and 4 (1%) had
adenosquamous carcinoma.
Staging. All patients underwent endoscopic esophageal
ultrasound (EUS) before treatment to determine clinical
stage. Clinical depth of tumor invasion (cT) and clinical
regional lymph node status (cN) were recorded by means of
the 1997 criteria of the American Joint Committee on Cancer
Staging.3 Ultrasound characteristics were primary determi-
nants of cN and included nodal size, shape, border, internal
echo characteristics, and proximity of the regional node to the
primary tumor. Distant metastatic disease (cM1b) was identi-
fied by computed tomographic scanning.
Pathologic stage (pT and pN) was determined by examina-
tion of the resection specimen and regional lymph nodes that
were either sampled or included in the lymphadenectomy
specimen.
Induction therapy. Since 1991, patients have been offered
induction therapy for cN1 and cT3 or cT4 cancers. Induction
therapy included two courses of chemotherapy, either cis-
platin and 5-fluorouracil4 or cisplatin and taxol.5 Concurrent
with chemotherapy, accelerated fractionation radiation thera-
py (1.5 Gy bid to a total dose of 45 Gy) was administered in
two courses over 2 months. Surgery was accomplished 4 to 6
weeks later. These studies were approved and reviewed annu-
ally by The Cleveland Clinic Foundation Institutional Review
Board, and written informed consent was obtained from all
patients before beginning treatment.
Surgery. Of 293 patients, 234 (80%) had esophagectomy
with thoracotomy and 2-field lymphadenectomy, and 59
(20%) had transhiatal esophagectomy and lymph node sam-
pling. Patients with cN1 and cT3 or cT4 cancers not receiv-
ing induction therapy underwent surgery as the primary treat-
ment. Six patients had pT4 tumors, all infracarinal.
Ninety-four percent had R0 resections.
Study end point. The end point of the study was all-cause
mortality. Patients were followed up by periodic clinic visits;
however, a cross-sectional systematic follow-up was made in
December 1999. Mean follow-up was 26 ± 15 months (43 ±
35 months in patients alive at last follow-up).
Methods—data analysis
Descriptive. Descriptive statistics are summarized as the
mean and standard deviation for continuous variables and as
frequencies and percentages for categorical variables.
Survival. Nonparametric estimates of survival are obtained
by the method of Kaplan and Meier.6 A parametric method
was used to resolve the number of phases of instantaneous
risk of death (hazard function) and to estimate their shaping
parameters.7 Estimates of survival were considered reliable to
a maximum of 10 years.
So that the prognostic relevance of clinical staging could be
established, a multivariable time-related analysis of survival
was performed of clinical staging, demographic, and surgical
experience variables (Appendix I), in the following manner.
Initial screening of variables possibly related to survival used
Table I. Patient groups
Group n Clinical stage Pathologic stage Treatment Survival
1 37 cN1 pN0 IT Intermediate
2 32 cN1 pN1 IT Poor
3 75 cN1 pN1 SURG Poor
4 79 cN0 pN0 SURG Good
5 23 cN0 pN0 IT Intermediate
6 8 cN0 pN1 IT Poor
7 21 cN0 pN1 SURG Poor
8 18 cN1 pN0 SURG Intermediate
IT, Induction therapy followed by surgery; Surg, surgery alone.
1 of cN1/pN1 patients undergoing surgery without induction
therapy; (3) all pN1 patients; (4) all pN0 patients; and (5)
pN0 patients, who underwent surgery without induction ther-
apy. We then performed a combined analysis with interaction
terms representing differences identified by the preliminary
subgroup analyses.
So that risk-adjusted estimates of the effect of being down-
staged by induction therapy to pN0 could be obtained, the
final multivariable model was solved for two 62-year-old
patients, both pT2 N0 M0 at thoracotomy, one downstaged to
that pathology by induction therapy. These estimates are
compared with a third 62-year-old patient at thoracotomy
with pN1 disease and three positive nodes. The cost of induc-
tion therapy in the patient downstaged to pN0 was estimated
as the area between the survival curves for the two pN0
patients. The benefit of induction therapy was estimated as
the area between the survival curve of the patient downstaged
to pN0 and the patient with pN1 disease.
Differences of areas represent the reduced and added years
of life within the 10 years after surgery contributed by down-
staging. For reasons previously given, these differences in
lifetime are presented with 90% confidence limits (CL).10
Presentation. Confidence limits of survival estimates are
equivalent to 1 standard error (68% CL). Tables of multivari-
able analyses are presented with their regression coefficients,
standard errors, and P values, rather than an expression of rel-
ative risk. This is because the transformation of scale of con-
tinuous and ordinal variables makes conversion of regression
coefficients to either odds ratios or hazard ratios uninter-
pretable. In addition, the hazard function models are not of
proportional hazards, further reducing the interpretability of
hazard ratios based solely on regression coefficients.
To obtain risk-adjusted estimates of the effect of N1 burden
on 1- and 5-year survival, we solved the final multivariable
equation for number of nodes from 1 to 10 with all other fac-
tors held constant: age 62 years, pN1 disease, no induction
therapy, use of thoracotomy, and no metastatic disease.
Results
Staging and downstaging
Surgery groups. A total of 193 patients were clinical-
ly staged, received no induction therapy, and were
treated with surgery (groups 3, 4, 7, and 8). Assessment
of clinical staging of regional lymph node status is pro-
vided by the comparison of clinical to pathologic stage
in these patients (Appendix Table II). The clinical
determination of N1 had 80% accuracy, 78% sensitivi-
ty, 81% specificity, 81% positive predictive value, and
79% negative predictive value.
Induction therapy groups. One hundred patients were
clinically staged and received induction therapy fol-
lowed by surgery (groups 1, 2, 5, and 6). Clinical stage
before induction and pathologic stage at resection are
listed in Appendix Table III. Efficacy of induction ther-
apy can be estimated by comparing the concordance
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the log-rank test and the univariable Cox proportional haz-
ards model. Continuous and ordinal variables were assessed
univariably by decile risk analysis to suggest transformations
of scale required to assure that the relationships of these mea-
sured variables were well calibrated to model of outcome.
Multivariable analysis was performed simultaneously for
the two hazard phases identified from the data. We used a
directed technique of entry of variables into the multivariable
models.8 A P = .1 criterion for retention of variables in the
final models was used. Additionally, bootstrap resampling
was used to validate the models.9
Who will respond to induction therapy? Among the 69 cN1
patients who received induction therapy, 37 were found to
have pN0 at operation and are classified as “responders.”
Multivariable logistic regression analysis was performed of
all pre-induction therapy variables (Appendix I) to identify
factors that would predict pN0.
Cost and benefit of therapy. Two avenues of inquiry were
taken to investigate the question, “Do patients receiving
induction therapy survive as long as their counterparts who
did not receive induction therapy?” If they do not, this would
suggest a toxic effect of therapy, advancement of the disease
during therapy, the biologic process of downstaging, or other
therapy-related differences.
Matched analysis. Even in a randomized study, finding
counterparts for such a comparison is impossible because
pathologic stage is unknown at the time of randomization.
Therefore, patients were multivariably propensity-matched
for their demography, pathologic stage, operation, and date of
operation (Appendix I). Matching factors associated with
induction therapy were identified by means of multivariable
logistic regression analyses and strategies for model building
similar to the survival analysis described above. After these
factors had been identified, statistically nonsignificant fac-
tors, including some components of pathologic stage, sex,
race, cell type, degree of differentiation of the tumor, surgical
approach, and date of operation were added to the analyses.
The resulting logistic equation yielded a propensity score for
each patient. Patients were then sorted according to their
score. This revealed that about one third (tercile I) of the
patients were unmatched (less than 10% chance of receiving
induction therapy). In addition, the 19 patients downstaged
by induction therapy to pT0/pN0 were unmatched. The
remaining two terciles were well matched (Appendix Table
I). The effect of induction therapy on survival was determined
within each tercile as a whole and separately for the pN1 and
pN0 cohorts.
Multivariable analysis. The second avenue of inquiry was
multivariable risk factor analysis. The analysis was directed
toward (1) identifying an incremental risk for death of induc-
tion therapy in both early and late hazard phases after
accounting for the strongest predictors of outcome (patholog-
ic stage variables) and (2) quantifying the cost if induction
therapy indeed downstaged the patient to pN0. Because we
anticipated a wide variability of risk, preliminary analyses
were performed on 5 subgroups of patients: (1) cN1/pN0 or
cN1/pN1, who received induction therapy; (2) the addition to
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and discordance of cN and pN between the surgery and
induction therapy groups. For surgery groups, concor-
dance of cN and pN was 80% (accuracy) and discor-
dance, 20%; for induction therapy groups, concordance
was 55% and discordance, 45%.
Survival
Surgery groups. Survival for the four surgical groups
(groups 3, 4, 7, and 8) is displayed in Fig 1. The
extremes of survival are seen in groups 3 (cN1/pN1)
and 4 (cN0/pN0). Patients who were understaged and
who were actually pN1 (group 7) had poor survival
similar to group 3. Patients who were overstaged and
who were actually pN0 (group 8) had intermediate sur-
vival. Compared with group 4, group 8 patients had a
similar cT, but a higher pT status (61% vs 14%),
despite both groups being pN0 (Table II).
Risk factors for death after esophagectomy without
induction therapy, restricted to those factors known
before induction therapy (Appendix I), included cN1
and increasing cT in cN0 patients (Table III).
Induction therapy groups. Survival for the four
groups (groups 1, 2, 5, and 6) receiving induction ther-
apy is displayed in Fig 2. Patients downstaged to pN0
(group 1) or cN0 patients who received IT (group 5)
had intermediate survival and a similar pT (16% and
22%, Table II). Patients not downstaged (group 2) or
patients understaged or progressing during induction
therapy (group 6) had poor survival similar to groups 3
and 7.
Who will respond to induction therapy? Cell type
was found to be associated with the “response” of cN1
disease. Fourteen of 17 patients with squamous cell
Fig 1. Survival in surgery group (no induction therapy). Survival, confidence limits, and number of patients still
alive (in parentheses) at 1 and 5 years were as follows: group 3, 49% ± 6% (30) and 9% ± 4% (4); group 4, 89%
± 4% (58) and 68% ± 7% (21); group 7, 52% ± 12% (8) and 13% ± 8% (2); group 8, 76% ± 10% (13) and 43% ±
13% (4).
Table II. Pathologic depth of tumor invasion for patient groups
cT3 and cT4 pT3 and pT4
Group Treatment n No. % No. %
1* IT 37 30 81 6 16
2 IT 32 25 78 26 81
3 SURG 75 69 92 70 93
4 SURG 79 15 19 11 14
5* IT 23 15 65 5 22
6 IT 8 4 50 4 50
7 SURG 21 15 71 15 71
8 SURG 18 15 83 11 61
IT, Induction therapy followed by surgery; Surg, surgery alone. 
*Downstaging of T and N by induction therapy.
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carcinoma converted to N0 (82%), in contrast to only
23 of 51 patients with adenocarcinoma (45%, P = .01).
The one patient with adenosquamous carcinoma under-
went induction therapy and did not respond.
Cost and benefit of therapy
Matched analysis. In general, patients receiving
induction therapy were younger, had N1 disease, and
greater T. This was true for both clinical stage (Table
IV) and pathologic stage (Table V). In well-matched
patients, there was a small, consistent, nonsignificant
difference in survival for similar pathologic stages in
patients receiving induction therapy (Appendix Table
VI). Survival of patients in well-matched terciles II and
III (Appendix Table I) had similar pattern of survival (P
= .4). In both terciles II and III, patients receiving
induction therapy had a slightly poorer survival at any
given point. In both terciles II and III, this pattern was
seen in pN0 patients (P = .4 and .6) and pN1 patients
(P = .8 and .2).
Multivariable analysis. Risk factor analysis based on
pN at esophagectomy (Table VI) revealed that induc-
tion therapy, after accounting for the substantial risk of
pN1, modestly increased early risk (Fig 3). In the typi-
cal patient, as shown by the areas beneath the survival
curves in Fig 3, induction therapy reduced expected
lifetime for a patient downstaged to pN0 by about one
third compared with a patient with pN0 disease not
receiving induction therapy. Nevertheless, the cost is
offset by a large, 17-fold increase in lifetime for such a
downstaged patient compared with pN1 disease.
Also, in the early hazard phase, there was an
increased risk of death for pN0 patients who underwent
thoracotomy. Late survival was affected by greater pT
in pN0 patients and by a greater number of N1 nodes in
pN1 patients (Fig 4). Pathologically identified metasta-
tic disease further reduced survival.
Discussion
Staging and downstaging. EUS is a powerful clinical
staging tool. In this study, accuracy in determination of
regional lymph node status (N1) was 80%. This may be
improved with future modifications of the equipment and
the addition of EUS-directed fine-needle aspiration of
regional lymph nodes. This technologic advance in clini-
Fig 2. Survival in induction therapy groups. Survival, confidence limits, and number of patients still alive (in paren-
theses) at 1 and 5 years were as follows: group 1, 68% ± 8% (25) and 37% ± 9% (5); group 2, 52% ± 9% (16) and
12% ± 6% (3); group 5, 52% ± 10% (12), and 35% ± 10% (5); group 6, 50% ± 18% (4) and 0% (0).
Table III. Clinical factors associated with mortality
after esophagectomy without preceding induction
therapy (groups 3, 4, 7, and 8)
Incremental risk factor Coefficient ± SD P value
cN1 disease 4.2 ± 0.71 <.0001
cT in cN0 patients* 1.07 ± 0.20 <.0001
SD, Standard deviation. 
*Clinical depth of tumor invasion has been expressed as an ordinal variable:
1 = cT < 1; 2 = cT1; 3 = cT2; and 4 = cT3 or cT4.
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cal staging has been aided by an accurate staging system
that can be used to group patients with similar prognoses.
Once tumors have metastasized to regional lymph
nodes, survival is poor. Surgery in these patients is lit-
tle more than palliation. The identification of N1 dis-
ease and downstaging with induction therapy to pN0
are possible. This is evident by the greater discordance
of cN and pN in the induction therapy group compared
with the surgery groups. The discordance (inaccuracy
of staging) seen in the surgery group was 20%. This
discordance rose to 45% in the induction therapy
groups. However, this is a combination of staging inac-
curacy and downstaging. Thus, about 25% to 30% of
patients will be downstaged to N0 by induction thera-
py. Unfortunately, accurate identification of responders
to induction therapy is not possible at present.
Survival. Regardless of treatment, patients with pN1
disease (groups 2, 3, 6, and 7) have poor survival. There
is slight modulation of survival in these patients by N1
burden. In pN0 disease (groups 1, 4, 5, and 8), survival
is intermediate to good and is substantially modulated
by induction therapy, pT, and type of operation.
Cost and benefit of therapy. Induction therapy in
pathologically matched patient groups produces a
small difference in survival and in multivariable analy-
sis a statistically significant difference. This difference
is the result of multiple factors, including induction
toxicity, the biologic process of downstaging that pro-
duces a lower stage that may not be equivalent to that
same stage in a patient not receiving induction therapy
(hysteresis effect of downstaging), possible progres-
sion of disease during therapy, and additional unknown
factors.
The cost of induction therapy in responders is con-
siderably outweighed by the survival benefit of conver-
sion to pN0. In the future, if nonresponders can be
identified, they can be spared the risks of induction
therapy.
Table IV. Clinical factors associated with induction
therapy 
Factor Logistic coefficient ± SD P value
Younger age* –4.9 ± 1.76 .005
Older age 0.29 ± 0.116 .01
cN1 disease 0.62 ± 0.28 .03
Depth of tumor invasion† (cT) –1.76 ± 0.81 .03
Intercept –1.14
SD, Standard deviation. 
*exp[age/50] exponential transformation.
†[1/cT] inverse transformation, where clinical depth of tumor invasion has
been expressed as an ordinal variable: 1 = cT < 1; 2 = cT1; 3 = cT2; and 4 =
cT3 or cT4.
Table V. Factors associated with induction therapy,
considering only pathologic information regarding the
cancer (19 patients with pT0 are excluded)
Factor Logistic coefficient ± SD P value
Younger age* –3.89 ± 1.12 .0005
Older age† 12.5 ± 4.3 .003
Higher pathologic stage‡ –3.3 ± 1.00 .0008
N1 burden§ –0.83 ± 0.21 .0001
Intercept –36.9
SD, Standard deviation. 
*exp[age(years)/50] exponential transformation.
†ln[age(years)] natural logarithmic transformation.
‡1/[pStage] inverse transformation, where pathologic stage has been
expressed as an ordinal variable: 0 = stage 0; 1 = stage I; 2 = stage IIA; 3 =
stage IIB; 4 = stage III; 5 = stage IVA; 6 = stage IVB.
§ln[number of positive nodes + 1] natural logarithmic transformation.
Table VI. Risk factors for death after esophagectomy
Incremental risk factor Coefficient ± SD P value
Early hazard phase (~3 y)
Older age* –2.6 ± 0.96 .007
pN1 disease 2.2 ± 0.66 .0008
Induction therapy 0.71 ± 0.26 .006
Thoracotomy in pN0 disease 1.75 ± 0.66 .008
Late hazard phase (>~3 y)
Greater depth of invasion (pT) in 
pN0 disease† 1.08 ± 0.24 < .0001
N1 burden‡ –7.9 ± 1.39 < .0001
Distant metastatic disease (M1a or M1b) 1.02 ± 0.41 0.01
SD, Standard deviation. 
*[50/age(years)] inverse transformation.
†Numerically expressed as an ordinal variable: 1 = T0; 2 = THGD; 3 = T1; 
4 = T2; 5 = T3; 6 = T4.
‡[1/(number of positive nodes + 1)] inverse transformation.
Table VII.  Use of thoracotomy
Thoracotomy
Group N No. %
1 37 36 97
2 32 32 100
3 75 65 87
4 79 37 47
5 23 22 96
6 8 8 100
7 21 19 90
8 18 15 83
Total 293 234 80
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Implications. Previous studies of induction thera-
py have ignored clinical stage and randomized
patients into surgery-only and multimodality arms,
assuming that randomization will be equal across
stages.11-14 This study illustrates several problems
with such trials. For patients with early-stage tumors
and excellent survival, small studies would be under-
powered to detect a therapeutic effect in this growing
segment of patients. In addition, including such
patients without accounting for stage may dilute the
therapeutic effect of induction therapy. Another prob-
lem of randomized trials in this setting is that they
may still be susceptible to the very selection bias they
are designed to protect against.15 Patients who are
deemed to have either good or bad therapy risk may
or may not be included at all in the trial. Further, as
Fig 3. Cost and benefit of induction therapy. Estimates are risk-adjusted using the multivariable equation from
Table VI. A, Time-related survival after esophagectomy in two 62-year-old patients, both pT2 N0 M0 at thoraco-
tomy, one of whom had been downstaged to pN0 by induction therapy. B, As in A, except that for comparison, a
similar pN1 patient with three positive lymph nodes is shown. The areas between the survival curves represent the
loss of lifetime (cost) or gain of lifetime (benefit) of induction therapy. The cost to the patient downstaged by induc-
tion therapy is a loss of 1.7 years (90% CL, 0.4-2.9) of lifetime over a 10-year period, from 5.3 to 3.6 years (upper-
most shaded area). The benefit is a gain of 3.4 years (90% CL, 2.5-4.4) of lifetime over the same 10-year period,
from 0.2 to 3.6 years (lower shaded area).
A
B
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shown by this study, there is inaccuracy in clinical
staging of about 20%. This is similar in magnitude to
the proportion of patients who may respond to induc-
tion therapy. Both inaccuracy and lack of response
will tend to dilute and hide the beneficial effect of
induction therapy (Appendix II).
Presently we depend on clinical stage to direct treat-
ment. The finding of cN1 predicts poor survival, and
those patients who are suitable candidates are offered
induction chemoradiation therapy and surgery in a pro-
tocol setting. Those patients who are understaged and
found to have N1 disease at resection are offered post-
operative adjuvant chemoradiation therapy. Although
this treatment protocol is not perfect, it has allowed
stratification of patients for both prognosis and evalua-
tion of therapy. We strongly recommend that all
patients with esophageal carcinoma be clinically staged
and have their treatment modified accordingly.
Limitations
Limitations of this study include the inaccuracy of
clinical staging and the inability to restage patients
accurately after induction therapy. This prompted the
addition of groups 5 through 8 to highlight these inac-
curacies and the realities of treatment of esophageal
cancer. Another limitation is that this is a modest-sized
nonrandomized study with treatment biases over time.
We have attempted to balance these problems with
propensity matching and multivariable analysis.
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Appendix I. Variables examined in multivariable
analyses
Demography
Sex, race, age (years)
Pre-induction therapy (or preoperative) clinical staging
Each clinical depth of tumor invasion (cT) stage 
(0, Tis, 1-4), an ordinal variable representing these 
(1 = cT0, 2 = cTis, 3 = cT1, 4 = cT2, 5 = cT3,
6 = cT4), and a dichotomous variable for cT > 2; clin-
ical N1 disease.
Pre-esophagectomy therapies
Previous esophagogastric operations
Preoperative induction therapy
Surgical approach
Thoracotomy versus transhiatal
Tumor characteristics
Cell type (adenocarcinoma, squamous cell, adenosqua-
mous); each histologic grade of tumor differentiation and
an ordinal variable representing differentiation (0 = well,
1 = moderately well, 2 = moderate, 3 = moderately poor,
and 4 = poor); R0 resection; presence of distant metas-
tases, either M1a or M1b.
Pathologic staging
Pathologic depth of tumor invasion (pT) expressed simi-
lar to clinical staging; pathologic N1 disease (pN1), num-
ber of nodes sampled, number of nodes positive, and per-
cent of nodes sampled found to be positive (both are
expressions of N1 burden); pathologic stage (pStage)
(ordinal variable, where 0 = stage 0, 1 = stage I, 2 = stage
IIA, 3 = stage IIB, 4 = stage III, 5 = stage IVA, 6 = stage
IVB).
Downstaging
Difference in T, difference in N.
Postoperative
Use of postoperative chemotherapy and/or radiotherapy
Surgical experience
Date of operation, expressed continuously as years
between January 1, 1985, and the date of esophagectomy
Note: All dichotomous variables were coded as 0 for absence
of the factor and 1 for presence of the factor. Thus, the factor pN1
disease (Table VI) is 0 for pN0 disease and 1 for pN1 disease.
Appendix II: Simulation of randomized trial of
induction therapy
We simulated a randomized clinical trial with these nonran-
domized patients by a propensity-matched analysis based on
preinduction therapy clinical staging (Table IV) and other non-
significant factors, as described in the “Methods” section. As in
the propensity matching using pathologic stage, only two ter-
ciles of patients were well matched. In tercile II, survival was
51% and 16% at 1 and 5 years in patients not receiving induc-
tion therapy, and 45% and 14% at these same times in patients
receiving induction therapy (P = .7). In tercile III, survival was
54% and 36% at 1 and 5 years in patients not receiving induc-
tion therapy, and 65% and 28% at these same times in patients
receiving induction therapy (P = .9). However, when these same
patients were included in a multivariable analysis of survival,
adjusting for propensity and pathologic stage at esophagecto-
my, a clear benefit of downstaging became evident (P = .0002).
Thus, the unadjusted comparison hid the benefit of induction
therapy for those who responded by downstaging.
Discussion
Dr Richard Whyte (Stanford, Calif). The objective was to
determine the relevance of clinical staging and the importance
of downstaging. The results, not surprisingly, showed that the
earlier stage patients did the best, the most advanced stage
patients did the worst, and the patients who received induction
therapy were somewhere in between. Furthermore, of those
that received induction therapy, patients with N1 disease did
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worse than those with N0 disease. This, I thought, was fairly
straightforward. The manuscript, on the other hand, was any-
thing but straightforward. Somehow the 1-page abstract was
transformed into 44 pages, including 9 tables, 6 figures, 2
appendixes, and enough statistics, including P values, adjusted
coefficients, confidence limits, terciles, propensity matching,
and mathematical modeling to make my head spin. To be fair,
however, much of the text and several of the figures are con-
tained in two appendixes, which detail the complex statistical
methods used to analyze the data. Nonetheless, I did indeed
find the statistics a challenge. I would like to thank both Craig
Miller, my colleague, for convincing me that the statistics are
both appropriate and, as he terms it, “the wave of the future,”
and Tom Rice for a quick tutorial on these statistics on
Appendix Table I. Propensity-matched terciles, based on pathologic information
Tercile I* Tercile II Tercile III
Variable No IT IT No IT IT P No IT IT P
No. 88 3 67 24 38 54
Male (%) 82 100 82 88 .5 84 80 .6
Age (y) 66 ± 12 70 ± 8 64 ± 10 61 ± 10 .2 58 ± 6.8 59 ± 7.5 .6
White (%) 100 100 96 92 .5 89 92 .6
Thoracotomy (%) 35 67 100 100 1.0 100 100 1.0
pT3/pT4 (%) 48 0 67 71 .7 53 44 .4
pN1 (%) 41 33 63 67 .7 47 43 .7
Positive nodes† 7 — 4 3.5 .8 2 2 .12
Adenocarcinoma (%) 92 33 81 88 .4 71 74 .8
Distant metastatic disease (M1a or M1b) (%) 0 0 15 17 .8 5 7 .7
pStage III or IV (%) 41 0 55 71 .18 39 32 .4
Poorly differentiated (%) 36 67 40 54 .2 55 52 .7
Date of operation‡ 10 ± 3.2 8.5 ± 3.6 9.1 ± 3.4 9.0 ± 3.1 .9 9.9 ± 3.9 9.9 ± 2.3 .9
IT, Induction therapy.
*No valid comparisons (essentially unmatched for induction therapy). Also note that no comparison could be made for the 19 patients downstaged by induction ther-
apy to pT0/pN0. 
†Median number in pN1 patients. 
‡Number of years between January 1, 1985, and date of esophagectomy.
Appendix Table II. Clinical (cN) and pathologic
(pN) stage in surgery groups 
Clinical stage
Pathologic stage cN1 cN0 Total
pN1
Group Group 3 Group 7
No. (%) 75 (39%) 21 (11%) 96
pN0
Group Group 8 Group 4
No. (%) 18 (9%) 79 (41%) 97
Total 93 100 193
The percentages are of n = 193. Groups 3 and 4 represent true “positives” and
“negatives,” respectively, and groups 8 and 7 false “positives” and “negatives,”
respectively.
Appendix Table III.  Preinduction therapy and
pathologic stage in induction therapy groups
Pre-IT stage
Pathologic stage cN1 cN0 Total
pN1
Group Group 2 Group 6
No. (%) 32 (32%) 8 (8%) 40
pN0
Group Group 1 Group 5
No. (%) 37 (37%) 23 (23%) 60
Total 69 31 100
Clinical (cN) and pathologic (pN) stage in preinduction therapy (pre-IT)
groups. Groups 2 and 5 represent true “positives” and “negatives,” respective-
ly, and groups 1 and 6 false “positives” and “negatives,” respectively.
Appendix Table IV.  Comparison of 1- and 5-year
survival after surgery without and with preceding
induction therapy in well-matched terciles
Survival (%)
Surgery Induction therapy
Tercile 1 y 5 y 1 y 5 y
II 58 28 48 16
pN0 79 49 50 38
pN1 44 16 48 14
III 65 23 61 22
pN0 73 33 68 35
pN1 57 11 52 7
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Thursday morning. Fortunately, Tom has chosen not to present
all of the statistics today but instead has chosen two key fea-
tures: the hazard functions and a simulated survival curve of a
hypothetical patient based on his mathematical model. This
model allows one to perform a simulated randomized trial of
two treatment modes. While the model takes into account
many of the quantitative aspects of patient selection, it fails to
account for some of the more qualitative issues such as patient
bias, physician bias, and patient performance status. To borrow
from Dr Matloff’s presentation, if one were to compare clini-
cal trials to government, I would submit that a randomized
prospective study is like democracy: it is not perfect but it is the
best system we have. 
I have 3 questions for Dr Rice. First, numerous other trials of
neoadjuvant therapy for esophageal cancer have shown that
complete pathologic response including both tumor and nodal
response is a predictor of better outcome. Why did this study
instead ignore tumor response and use an assumption of nodal
response? I say assumption since there is generally no pretreat-
ment proof of N1 disease. What was the complete pathologic
response rate in these patients with post-treatment N0 disease?
Dr Rice. The problem with clinical staging is that the
pathologic stage is not known until all the treatment is com-
pleted. If induction therapy is successful, then the pathologic
stage is changed. I agree that patients who have a complete
response, no residual tumor, are the best group of patients.
Twenty percent of our patients had complete sterilization of
the tumor and the regional lymph nodes with induction ther-
apy. However, those patients who were T0 but still N1 at
resection had a poor survival. So sterilization of the tumor is
not the key. Regional lymph node downstaging is crucial. We
did not include the data on T downstaging because it made
the presentation and paper even more complex. I plan to write
a companion article about the implications of T staging and
downstaging. Twenty percent of our patients had sterilization
of the tumor and regional nodes, and approximately 30%, a
third of the patients, had sterilization of regional nodes.
Dr Whyte. My second question concerns the clinical stag-
ing. You had an error rate of 20% based on clinical staging—
including both false positives and false negatives. Would this
justify more aggressive surgical staging such as more liberal
use of needle biopsies, EUS-guided needle biopsies, or tho-
racoscopic or laparoscopic staging?
Dr Rice. Staging is in its infancy and is certainly evolving.
No doubt clinical staging will improve with improved instru-
ments and technology. The addition of EUS-guided fine nee-
dle aspiration of regional nodes will improve the determina-
tion of regional lymph node status. Thoracoscopic and
laparoscopic staging, which is not the equivalent of medi-
astinoscopy in lung cancer, is hard to do. It is a difficult pro-
cedure that is essentially another operation. It should be
reserved for those questions that are not answered by clinical
staging. There is a role for invasive staging, but not in every
patient. 
Dr White. Should we now consider a simulated or, to use
the computer parlance of the day, a “virtual” randomized
study to settle these types of questions, particularly when
there are true randomized studies or randomized clinical tri-
als that address the same question yet fail to find significant
differences in the two treatment arms?
Dr Rice. Simulated randomization would never replace a
truly randomized phase III study. However, the present studies
as they were conceived do not randomize patients by stage. This
is a major problem, because the small effect of induction thera-
py on a few patients is hidden by the inclusion of very good risk
patients. Not until we have sophisticated studies that randomize
patients by stage, are well conducted, and are adequately ana-
lyzed are we ever going to have a phase III study that will
answer the questions. If we continue to conduct studies of
esophageal cancer as we have, every study will be a negative
study. The answers will be hidden because of the inadequacies
of the preparation and conduct of the study.
Dr Donald Low (Seattle, Wash). Dr Rice, I enjoyed your
paper as well. Previous publications, however, have tended to
take the nodal status issue and look on it not only positive-neg-
ative but number of nodes positive and number of stations pos-
itive. Did you substratify the patients who were pN1 positive to
the number of nodes and to the number of stations positive? 
Dr Rice. We did analyze by number of positive nodes.
There is an exponential decreasing survival. The break point
is at three positive nodes. After, survival plateaus at a very
low level. With one node positive, 5-year survival is about
40%, with two nodes positive it is a bit less than 20%, and
once there are three nodes or more positive, 5-year survival is
less than 5%. The percentage of lymph nodes positive in
resection specimens is also important, and the break point is
around 20%. We did not look at the number of perihilar sta-
tions. There is no doubt that lymph node burden is crucial in
further defining N1 disease.
James Mark (Stanford, Calif). I was struck with the stag-
ing question also. You had some cN1 pN0 patients who were
operated on alone. In other words, nothing had been given
them and they were overstaged before the operation. I would
suggest that if you are going to use patients like that as a con-
trol or use noninvasive staging to get those answers, you sub-
tract that number from the ones that are downstaged by
induction therapy, because some are downstaged with no
therapy.
Dr Rice. Understaging/overstaging was included in the
analysis. The analysis in the paper includes 8 groups: the 4
additional groups were patients overstaged, patients under-
staged, N0 patients who received induction therapy because
of advanced T, and patients who were cN0 at induction but
were pN1 at resection; this represents either misstaging or
progression on treatment. The analysis of all 8 groups gets
pretty complex. For simplicity, I presented 4 groups that
encompass the two main concepts, staging and downstaging.
The detailed analysis of all 8 groups is included in the paper.
